Table 1. . Sample characteristics.
| Characteristic | Value |
|---|---|
| Gender | |
| Male | 52 (68%) |
| Female | 24 (32%) |
| Treatment | |
| TACE + B | 38 (50%) |
| TACE | 38 (50%) |
| Age (years) | |
| Median (range) | 70 (45–87) |
| Tumor size (mm) | |
| Median (range) | 40 (5–110) |
| Tumor nodules, n (%) | |
| 1–2 | 8 (11%) |
| 3–4 | 23 (30%) |
| >5 | 45 (59%) |
| Lobar side | |
| Right | 21 (28%) |
| Left | 21 (28%) |
| Bilobar | 34 (44%) |
| Time from diagnosis to live metastases | |
| Median (range), years | 0.6 (0–2.22) |
| Synchronous | 20 (26%) |
| Metachronous | 56 (74%) |
| Previous chemotherapy lines (n) | |
| 1 | 16 (21%) |
| 2 | 27 (36%) |
| 3 | 20 (26%) |
| 4 | 13 (17%) |
| Previous surgery | |
| Primitive tumor surgery | 48 (63%) |
| Metastasectomy | 5 (7%) |
| None | 23 (30%) |
| Liver involvement | |
| <50% | 46 (61%) |
| >50% | 30 (39%) |
| KRAS status | |
| Mutated | 35/76 (55%) 25/38 (66%) TACE + B 10/38 (26%) TACE |
| Wild-type | 31/76 (45%) 13/38 (32%) TACE + B 28/38 (74%) TACE |
| Performance status median (range) | 0 (0–2) |
| Baseline | |
| 0 | 51 (67%) |
| 1 | 23 (30%) |
| 2 | 2 (3%) |
| 1 month | |
| 0 | 42 (55%) |
| 1 | 26 (34%) |
| 2 | 8 (11%) |
| 3 months | |
| 0 | 34 (44%) |
| 1 | 27 (36%) |
| 2 | 15 (20%) |
| 6 months | |
| 0 | 30 (39%) |
| 1 | 28 (37%) |
| 2 | 18 (24%) |
B: Bevacizumab; TACE: Transarterial chemoembolization.